CN119097618A - 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物 - Google Patents

用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物 Download PDF

Info

Publication number
CN119097618A
CN119097618A CN202411228005.XA CN202411228005A CN119097618A CN 119097618 A CN119097618 A CN 119097618A CN 202411228005 A CN202411228005 A CN 202411228005A CN 119097618 A CN119097618 A CN 119097618A
Authority
CN
China
Prior art keywords
disorder
disease
subject
syndrome
leucine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411228005.XA
Other languages
English (en)
Chinese (zh)
Inventor
M·法克拓尔
T·菲尔茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intrabio Ltd
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of CN119097618A publication Critical patent/CN119097618A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202411228005.XA 2019-03-02 2020-03-02 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物 Pending CN119097618A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201962812987P 2019-03-02 2019-03-02
US62/812,987 2019-03-02
US201962842296P 2019-05-02 2019-05-02
US62/842,296 2019-05-02
US201962888894P 2019-08-19 2019-08-19
US62/888,894 2019-08-19
US201962895144P 2019-09-03 2019-09-03
US62/895,144 2019-09-03
CN202080029158.5A CN114040757B (zh) 2019-03-02 2020-03-02 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物
PCT/IB2020/051767 WO2020178721A1 (en) 2019-03-02 2020-03-02 Leucine, acetyl leucine, and related analogs for treating disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080029158.5A Division CN114040757B (zh) 2019-03-02 2020-03-02 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物

Publications (1)

Publication Number Publication Date
CN119097618A true CN119097618A (zh) 2024-12-10

Family

ID=69845470

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411228005.XA Pending CN119097618A (zh) 2019-03-02 2020-03-02 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物
CN202080029158.5A Active CN114040757B (zh) 2019-03-02 2020-03-02 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080029158.5A Active CN114040757B (zh) 2019-03-02 2020-03-02 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物

Country Status (25)

Country Link
US (1) US20220142959A1 (https=)
EP (2) EP4464378A3 (https=)
JP (2) JP7555346B2 (https=)
KR (2) KR102941068B1 (https=)
CN (2) CN119097618A (https=)
AU (2) AU2020231189B2 (https=)
BR (1) BR112021017203A2 (https=)
CA (1) CA3131948A1 (https=)
DK (1) DK3934637T3 (https=)
ES (1) ES2990183T3 (https=)
FI (1) FI3934637T3 (https=)
HR (1) HRP20241150T1 (https=)
HU (1) HUE068527T2 (https=)
IL (2) IL285870B2 (https=)
LT (1) LT3934637T (https=)
MA (1) MA55199B1 (https=)
MD (1) MD3934637T2 (https=)
MX (2) MX2021010568A (https=)
PL (1) PL3934637T3 (https=)
PT (1) PT3934637T (https=)
RS (1) RS65849B1 (https=)
SG (1) SG11202109512SA (https=)
SI (1) SI3934637T1 (https=)
SM (1) SMT202400334T1 (https=)
WO (1) WO2020178721A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
JP7471298B2 (ja) * 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル-ロイシンの重水素化類似体
US20250025442A1 (en) * 2020-12-10 2025-01-23 Texas Tech University System BCAA-Lowering Compounds for Prevention and/or Treatment of Alzheimer's Disease and Related Disorders
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease
WO2024243004A2 (en) * 2023-05-19 2024-11-28 The Children's Hospital Of Philadelphia Compositions and methods for treating traumatic brain injury
WO2025166100A1 (en) * 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders
WO2025175092A1 (en) * 2024-02-14 2025-08-21 Intrabio Inc. Acetyl leucine for treating syngap1-related disorders
WO2025264957A2 (en) * 2024-06-20 2025-12-26 Intrabio Inc. Acetyl leucine for treating neurodevelopmental disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
SMT201600385T1 (it) 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
US20140080885A1 (en) * 2012-09-13 2014-03-20 University Of South Florida (A Florida Non-Profit Corporation) Methods of treating traumatic brain injury
US10905670B2 (en) * 2016-04-19 2021-02-02 Intrabio Ltd. Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
TN2016000259A1 (en) * 2016-06-27 2017-10-06 Rekik Raouf Salbutamol (albuterol) eye protective medicament.
WO2018029658A1 (en) * 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases
NZ750391A (en) 2016-08-11 2026-03-27 Intrabio Ltd Pharmaceutical compositions and uses directed to lysosomal storage disorders
WO2019036442A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF NEURONAL INJURY

Also Published As

Publication number Publication date
SG11202109512SA (en) 2021-09-29
ES2990183T3 (es) 2024-11-29
CN114040757A (zh) 2022-02-11
IL285870B2 (en) 2025-12-01
MA55199A (fr) 2022-01-12
SMT202400334T1 (it) 2024-09-16
IL321899A (en) 2025-09-01
CA3131948A1 (en) 2020-09-10
US20220142959A1 (en) 2022-05-12
IL285870B1 (en) 2025-08-01
EP3934637A1 (en) 2022-01-12
RS65849B1 (sr) 2024-09-30
LT3934637T (lt) 2024-08-26
BR112021017203A2 (pt) 2021-12-14
JP2024170602A (ja) 2024-12-10
EP4464378A3 (en) 2025-04-09
MD3934637T2 (ro) 2024-12-31
KR102941068B1 (ko) 2026-03-18
JP2022522819A (ja) 2022-04-20
AU2020231189A1 (en) 2021-09-30
MX2024015063A (es) 2025-01-09
EP3934637B1 (en) 2024-07-31
PT3934637T (pt) 2024-08-30
JP7555346B2 (ja) 2024-09-24
MX2021010568A (es) 2021-11-12
HRP20241150T1 (hr) 2024-11-22
AU2025204995A1 (en) 2025-07-17
WO2020178721A1 (en) 2020-09-10
PL3934637T3 (pl) 2024-10-14
AU2020231189B2 (en) 2025-07-24
FI3934637T3 (fi) 2024-09-02
DK3934637T3 (da) 2024-09-02
KR20250171484A (ko) 2025-12-08
SI3934637T1 (sl) 2024-10-30
IL285870A (en) 2021-10-31
CN114040757B (zh) 2024-09-20
KR20210135272A (ko) 2021-11-12
MA55199B1 (fr) 2024-08-30
HUE068527T2 (hu) 2025-01-28
EP4464378A2 (en) 2024-11-20

Similar Documents

Publication Publication Date Title
CN114040757B (zh) 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物
US11116773B2 (en) Method of treating dementia
KR20190039227A (ko) 신경퇴행성 질병을 위한 치료제
US12594255B2 (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
US11690849B2 (en) Method of treating dementia
JP2022536017A (ja) 精神障害、行動障害、認知障害を処置する方法
HK40111810A (en) Leucine, acetyl leucine, and related analogs for treating disease
RU2815373C2 (ru) Лейцин, ацетиллейцин и родственные аналоги для лечения заболевания
JP7659940B2 (ja) ビンポセチンを用いる近視の治療方法
CN121443298A (zh) 用于治疗持续性脑震荡后症状的苯加兰他敏
HK40064685A (en) (n-)acetyl-l-leucine for use in treating traumatic brain injury
HK40064685B (en) (n-)acetyl-l-leucine for use in treating traumatic brain injury
CN118302163A (zh) α-1062用于治疗创伤性脑损伤
WO2014187226A1 (zh) 左旋甲氟喹在制备预防神经病理性疼痛药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination